Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366753 | 0.87 | ALDH1A1 (0.47) | MEN1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL4410079 | 0.83 | ALDH1A1 (0.44) | MEN1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL15392207 | 0.83 | HSP90AA1 (0.45) | MEN1ALDH1A1KMT2APKMCYP2D6 | |
| SCHEMBL5606072 | 0.83 | KMT2A (0.44) | MEN1ALDH1A1KMT2APKMCYP2D6 | |
| SCHEMBL1057833 | 0.81 | AGXT (0.48) | MEN1ALDH1A1KMT2APKMCYP2C19 | |
| SCHEMBL19823385 | 0.80 | PRMT5 (0.48) | MEN1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL4415374 | 0.74 | HPGD (0.39) | MEN1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL2888208 | 0.74 | MEN1 (0.46) | MEN1ALDH1A1KMT2APKMCYP2C19 | |
| SCHEMBL19824081 | 0.72 | MAPT (0.44) | MEN1ALDH1A1KMT2APKMMAPT | |
| SCHEMBL14321903 | 0.71 | PRMT5 (0.48) | MEN1ALDH1A1KMT2APKMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311795-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | CALASIA PHARMACEUTICALS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2013172872-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | CALASIA PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| EP-2012791-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007092496-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | HSP90B1, HSP90AB2P, HSP90AB1 | MEN1 3406/4885ALDH1A1 2635/4885KMT2A 4580/4885 |
| US-20160311795-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | HSP90B1, HSP90AB2P, HSPE1 | MEN1 4787/4885ALDH1A1 2259/4885KMT2A 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.